FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)

View source ↗

Summary

FDA approved a supplemental application for COMETRIQ (cabozantinib) submitted by Exelixis, Inc. The action updates the labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• COMETRIQ (CABOZANTINIB)

Snippet

SUPPL AP for COMETRIQ (CABOZANTINIB)